Epilepsy trial studies new drug to treat severe seizures
UC Department of Neurology one of 50 trial sites nationwide
A new clinical trial at the University of Cincinnati will study a new treatment for the most severe and deadly form of epilepsy.
Brandon Foreman, MD, is the site principal investigator at UC for the Researching Established Status Epilepticus Treatment (RESET) study, a trial being conducted across approximately 50 hospital emergency departments across the country.
SE basics
The trial focuses on a condition known as status epilepticus (SE), a disorder Foreman described as “seizures that don’t stop.” SE is the second most common neurologic emergency in the United States, and more than 150,000 Americans experience SE each year. Based on factors including age and the cause and duration of the seizures, between 20% to 30% of patients with SE do not survive.
About half of patients who have SE have a previous history of epilepsy and seizures, but the other half have no history of seizures. When a seizure goes on for more than five minutes, Foreman said it enters a “dangerous territory” where the seizure may not stop on its own without medication.
The current standard treatments for SE include paramedics administering drugs on the way to the hospital that activate specific GABA receptors in the brain that sit on the ends of neurons. These receptors communicate to slow down other neurons, so strengthening that connection helps suppress seizures.
A large dose of anti-seizure medication is then given once a patient reaches the hospital. But about a quarter of patients’ seizures still do not stop after receiving these initial medications.
“Right now the only way to manage them is to put them on anesthetic medications, so it’s a continuous drip medication to induce coma,” said Foreman, associate professor and associate director of neurocritical care research in the Department of Neurology and Rehabilitation Medicine in UC’s College of Medicine and a UC Health physician. “And that’s been associated with some bad outcomes. It’s not a good thing to come into the ICU and then be put into a coma, and there’s nothing to fill the gap.”
If we can avoid patients not progressing to the need for IV anesthesia, intubation and an ICU stay that can sometimes be prolonged, that’s going to be lifesaving.
Brandon Foreman, MD
Trial details
Foreman said the RESET study will test a new medication that will be administered after the first anti-seizure medication in emergency departments for those patients whose seizures persist.
“We’re pushing this medication forward in care so it’s actually hopefully fitting in that gap where they’re getting the second anti-seizure medication and we can stave off the progression to needing anesthesia to really get these under control,” he said.
The GABA receptors targeted by the first line of drugs administered in ambulances can melt away during a seizure, Foreman noted, making the drugs less effective at stopping the seizure. The drug being studied in the trial, ganaxolone, works differently.
“It’s a neurosteroid, so it’s a derivative of something your brain already makes,” Foreman said. “It’s hitting a very similar inhibitory transmitter or channel, but it’s doing so using those receptors that haven’t melted away as a result of the seizures.”
Patients who come into the emergency department with SE that doesn’t stop after the initial round of medications will be enrolled into the RESET study, with the trial drug added to the current standard of care.
“It’s not a medicine that [is administered] for weeks or that they can take as an outpatient; it’s a study that’s pretty short in general,” Foreman said. “It’s just while you’re there in the [emergency department], and our endpoint is just looking if the seizures stop.”
Foreman said if the drug stops seizures before the need for a medically induced coma, it will fill a significant gap in care for SE.
“If we can avoid patients not progressing to the need for IV anesthesia, intubation and an ICU stay that can sometimes be prolonged, that’s going to be lifesaving,” he said. “It’s probably going to improve outcomes dramatically for people that are responsive to this kind of treatment.”
Exception from informed consent
Because of the short time frame where drugs can be given to stop SE, the RESET study will operate with an exception from informed consent, or EFIC. This means patients will automatically be enrolled due to the life-threatening nature of the emergency, and then the patient or a family member can give consent to be part of the study after the fact.
“There’s actually not any time to go find family and walk them through the consent process and get them to sign and then talk to the investigational pharmacy about sending up the drug,” Foreman said. “All of that stuff can take an hour, and someone can’t seize for an hour. It’s really, really detrimental to their health.”
Even after receiving the drug in the emergency department, patients can withdraw consent to be part of the study going forward. Community members who wish to opt out of the study proactively by requesting an opt-out bracelet can learn more on the study’s website.
Featured photo at top of ambulance. Photo/Camilo Jimenez/Unsplash.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Bono, Chris Tucker Visit UC To Discuss Africa
December 5, 2002
U2's Bono and comedian-actor Chris Tucker led a delegation from the DATA organization who came to UC to talk about potentially catastrophic problems in Africa.
New Year's Help for Those Looking to Kick the Habit
December 20, 2002
Quitting smoking consistently ranks among the top three resolutions made by New Year's resolvers each year.
E-BRIEF: Let's Toast to a Healthier 2003
January 8, 2003
The New Year often means a new health kick: Vows to tone up and trim down, and maybe going to the doctor and getting ourselves as regularly "maintenanced" as we do our cars. So, this week's University of Cincinnati e-briefing examines the health concerns of the young and old, and what you should be doing to preserve your good health.
Today's ML King Events: One On, One Off
January 8, 2003
A memorial march, presentations, poetry and dance will pay tribute to the slain civil rights leader.
UC Named Lead Organization for OSHA Training Consortium
January 13, 2003
UC Continuing Medical Education (CME) has been selected as the lead organization for the Occupational Safety and Health Administration (OSHA) Great Lakes Training Consortium by the U.S. Department of Labor.
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 13, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
Ignorance of Stroke s Warning Signs a Barrier to Treatment; More Education Needed, UC Researchers Report in JAMA
January 14, 2003
Demographic groups facing the greatest risk of death and disability from stroke are the least likely to recognize stroke s warning signs and risk factors, according to a study by UC researchers published in the January 15 issue of the Journal of the American Medical Association (JAMA).
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 20, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
UC Researchers Find New Link Between the Eye and the Clock in the Brain
January 21, 2003
Results of a study done by a team of researchers working in the laboratories of Michael Lehman, PhD, professor, Department of Cell Biology, Neurobiology, and Anatomy at the UC College of Medicine, will appear in the February issue of Nature Neuroscience.
Leader of Fetal Surgery to Deliver Lectures at UC
January 31, 2003
An internationally recognized authority on fetal surgery will lecture at the UC Medical Center, representing the first of a series of lectures on fetal surgery presented by the department of Obstetrics and Gynecology (Ob/Gyn).